CELEX: 62018TA0377
Language: en
Date: 2019-06-28 00:00:00
Title: Case T-377/18: Judgment of the General Court of 28 June 2019 — Intercept Pharma and Intercept Pharmaceuticals v EMA (Access to documents — Regulation (EC) No 1049/2001 — Documents held by EMA containing information submitted by the applicants in the context of the marketing authorisation for the medicinal product Ocaliva — Decision to grant a third party access to a document — Exception relating to the protection of court proceedings)

26.8.2019   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 288/51
            
         
      Judgment of the General Court of 28 June 2019 — Intercept Pharma and Intercept Pharmaceuticals v EMA
      (Case T-377/18) (1)
      
      (Access to documents - Regulation (EC) No 1049/2001 - Documents held by EMA containing information submitted by the applicants in the context of the marketing authorisation for the medicinal product Ocaliva - Decision to grant a third party access to a document - Exception relating to the protection of court proceedings)
      (2019/C 288/64)
      Language of the case: English
      
         Parties
      
      
         Applicants: Intercept Pharma Ltd (Bristol, United Kingdom) and Intercept Pharmaceuticals, Inc., (New York, New York, United States), (represented by: L. Tsang, J. Mulryne, E. Amos and H. Kerr-Peterson, Solicitors, and F. Campbell, Barrister)
      
         Defendant: European Medicines Agency (represented by: initially by S. Marino, S. Drosos, A. Rusanov and T. Jabłoński, and subsequently by S. Marino, S. Drosos, T. Jabłoński, R. Pita and G. Gavriilidou, Agents)
      
         Re:
      
      Action under Article 263 TFEU for the annulment of EMA decision ASK-40399 of 15 May 2018, granting to a third party, pursuant to Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents (OJ 2001 L 145, p. 43), access to a document containing information submitted in the context of an application for marketing authorisation for the medicinal product Ocaliva.
      
         Operative part of the judgment
      
      The Court:
      
                  1.
               
               
                  
                     Dismisses the action;
                  
               
            
                  2.
               
               
                  
                     Orders Intercept Pharma Ltd and Intercept Pharmaceuticals, Inc. to pay the costs.
                  
               
            
         (1)  OJ C 311, 3.9.2018.